Clinical trials: Advanced Intestinal Cancer
Colorectal Cancer, Metastatic Colorectal Cancer
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab.
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Colon Cancer
- Trial name
- NCT03712943
- Testing
- Regorafenib, Nivolumab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Recurrent or Metastatic Colorectal Cancer
Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Based on the pervious data, aflibercept in combination with FOLFIRI is one of the effective 2nd line treatment option in advanced colorectal cancer.
- Trial name
- NCT04810585
- Testing
- Aflibercept + FOLFIRI
- Where
- South Korea
- Volunteers
- 153 people
- Sponsor
- Yonsei University
Irritable Bowel Syndrome, Colitis, Ulcerative
Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
This clinical trial hypothesize that Gut Microbiota (bacteria, viruses, fungi)play a major role in the occurrence and progression of many chronic gastrointestinal diseases like Irritable Bowel Syndrome, Inflammatory Bowel…
- Conditions
- Irritable Bowel Syndrome, Colitis, Ulcerative, Crohn Disease, Colonic Neoplasms
- Trial name
- NCT01099111
- Where
- Saudi Arabia
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- King Fahad Medical City
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Colon Cancer
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy.
- Trial name
- NCT03426904
- Testing
- Neoadjuvant FOLFOX, Conventional adjuvant FOLFOX
- Where
- 4 sites in South Korea
- Volunteers
- 708 people
- Sponsor
- Kyungpook National University Hospital
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
Rectal Neoplasms
Non-operative Management for Locally Advanced Rectal Cancer
This is a 5 year Phase II study to evaluate the safety of non-operative management (NOM) in patients with low rectal cancer (LRC) who achieve a complete clinical response (cCR) following chemoradiotherapy (CRT).
- Trial name
- NOM (NCT03179540)
- Testing
- Non-operative management
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Mount Sinai Hospital, Canada
Rectal Neoplasms, Rectal Neoplasm Malignant
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer.
- Trial name
- NCT04926324
- Testing
- Niraparib, Dostarlimab, Short course radiation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Iowa
Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine…
- Conditions
- Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma
- Trial name
- NCT05759923
- Testing
- OATD-02
- Where
- 3 sites in Poland
- Volunteers
- 40 people
- Sponsor
- Molecure S.A.
Colorectal Cancer
Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells
The study will enroll patients with metastatic colorectal cancer receiving chemotherapy. A total of approximately 22 cc of blood will be drawn during various chemotherapy infusions.
- Trial name
- NCT01286883
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Milton S. Hershey Medical Center
Colorectal Cancer
High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28
This trial aims to evaluate the efficacy, safety of high-dose FOLFIRI regimen in advanced colorectal cancer patients with wild-type UGT1A1*6 and *28.
- Trial name
- NCT03329183
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Changzheng Hospital
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
This study is a single-arm, open-label, exploratory clinical trial. Building on the previous dose-escalation trial, this dose-expansion trial aims to evaluate the safety and tolerability of intravenous monotherapy with CD-GA-102…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Recurrent, Colorectal Cancer Stage IV
- Trial name
- NCT07050394
- Testing
- CD-GA-102
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Changzheng Hospital
Pancreatic Cancer, Metastatic Breast Cancer
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment.
- Conditions
- Pancreatic Cancer, Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Colon Cancer
- Trial name
- NCT03073473
- Testing
- NantHealth GPS Cancer Test
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cota Inc.
Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer
Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer
This multicenter retrospective study aims to evaluate and optimize combination immunotherapy strategies for patients with microsatellite stable (MSS), microsatellite instability-low (MSI-L), or mismatch repair-proficient (pMMR)…
- Conditions
- Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy
- Trial name
- NCT06849362
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yue Gou
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Colon Adenoma, Colon Polyp
St. Paul's Advanced Resection Center Cohort for Colorectal Neoplasia (SPARC-C)
The SPARC-C study is a prospective, multi-institutional observational study of patients referred for the management of large (≥ 20mm) non-pedunculated colorectal polyps (LNPCPs).
- Conditions
- Colon Adenoma, Colon Polyp, Colon Lesion
- Trial name
- SPARC-C (NCT05402696)
- Testing
- Endoscopic tissue resection
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- University of British Columbia
Cancer, BRAF V600 Mutation
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF…
- Conditions
- Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer
- Trial name
- ENHANCE (NCT05275374)
- Testing
- XP-102, Trametinib
- Volunteers
- 221 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.